National, Multicenter, Observational Study Evaluating Prevalence, Virological and Clinical Characteristics of Chronic Hepatitis Delta in Romania and Assess Efficacy of Peg-interferon Alfa-2a Treatment in Patients With Chronic Hepatitis D (CHD)
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis D
- Focus Therapeutic Use
- Sponsors Roche
- 26 Oct 2016 Status changed from active, no longer recruiting to discontinued.
- 20 Oct 2014 Planned End Date changed from 1 Mar 2015 to 1 Oct 2014 according to ClinicalTrials.gov record.
- 14 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Mar 2015 according to ClinicalTrials.gov record.